Assessing prostate cancer growth with citrate measured by intact tissue proton magnetic resonance spectroscopy

Prostate Cancer and Prostatic Diseases

Volumn 15, Issue 3, 2012, Pages 278-282

  Dittrich, R ^a,b   Kurth, J ^a,b   Decelle, E A ^a   Defeo, E M ^a   Taupitz, M ^b   Wu, S ^a   Wu, C L ^a   McDougal, W S ^a   Cheng, L L ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

citrate; high resolution magic angle spinning; magnetic resonance spectroscopy; PSA density, percent free PSA; PSA velocity

Indexed keywords

CITRIC ACID; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE ASSOCIATION; GROWTH RATE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; OUTCOME ASSESSMENT; PATIENT SELECTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; PROTON NUCLEAR MAGNETIC RESONANCE; QUANTITATIVE ANALYSIS; TISSUE LEVEL; TUMOR VOLUME;

ADULT; AGED; CITRIC ACID; DISEASE PROGRESSION; EPITHELIUM; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 84865309624     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2011.70     Document Type: Article

References (36)

1. Andriole GL, Crawford ED, Grubb III RL, Buys SS, Chia D, Church TR et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360: 1310 - 1319.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2010; 61: 69 - 90.
3. Epstein JI. An update of the Gleason grading system. J Urol 2010; 183: 433 - 440.
4. Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 2003; 169: 517 - 523.
5. Klotz L. Active surveillance versus radical treatment for favorable-risk localized prostate cancer. Curr Treat Options Oncol 2006; 7: 355 - 362.
6. Hall MJ, DeFrances CJ, Williams SN, Golosinskiy A, Schwartzman A. National Hospital Discharge Survey: 2007 summary. Natl Health Stat Report 2010; 29: 1-20, 24.
7. Gore JL, Kwan L, Lee SP, Reiter RE, Litwin MS. Survivorship beyond convalescence: 48-month quality-of-life outcomes after treatment for localized prostate cancer. J Natl Cancer Inst 2009; 101: 888 - 892.
8. Fradet Y. Biomarkers in prostate cancer diagnosis and prognosis: Beyond prostate-specific antigen. Curr Opin Urol 2009; 19: 243 - 246.
9. Fiorentino M, Capizzi E, Loda M. Blood and tissue biomarkers in prostate cancer: State of the art. Urol Clin North Am 2010; 37: 131 - 141, Table of Contents.
10. Ploussard G, de la Taille A. Urine biomarkers in prostate cancer. Nat Rev Urol 2010; 7: 101 - 109.
11. Sardana G, Dowell B, Diamandis EP. Emerging biomarkers for the diagnosis and prognosis of prostate cancer. Clin Chem 2008; 54: 1951 - 1960.
12. Swanson GP, Basler JW. Prognostic factors for failure after prostatectomy. J Cancer 2010; 2: 1-19.
13. Franklin RB, Feng P, Milon B, Desouki MM, Singh KK, Kajdacsy-Balla A et al. hZIP1
14. zinc uptake transporter down regulation and zinc depletion in prostate cancer. Mol Cancer 2005; 4: 32.
15. Costello LC, Franklin RB, Feng P, Tan M, Bagasra O. Zinc and prostate cancer: A critical scientific, medical, and public interest issue (United States). Cancer Causes Control 2005; 16: 901 - 915.
16. Huang L, Kirschke CP, Zhang Y. Decreased intracellular zinc in human tumorigenic prostate epithelial cells: A possible role in prostate cancer progression. Cancer Cell Int 2006; 6: 10.
17. Golovine K, Makhov P, Uzzo RG, Shaw T, Kunkle D, Kolenko VM. Overexpression of the zinc uptake transporter hZIP1 inhibits nuclear factor-kappaB and reduces the malignant potential of prostate cancer cells in vitro and in vivo. Clin Cancer Res 2008; 14: 5376 - 5384.
18. Makhov P, Golovine K, Uzzo RG, Wuestefeld T, Scoll BJ, Kolenko VM. Transcriptional regulation of the major zinc uptake protein hZip1 in prostate cancer cells. Gene 2009; 431: 39 - 46.
19. Ghosh SK, Kim P, Zhang XA, Yun SH, Moore A, Lippard SJ et al. A novel imaging approach for early detection of prostate cancer based on endogenous zinc sensing. Cancer Res 2010; 70: 6119 - 6127.
20. Cortesi M, Fridman E, Volkov A, Shilstein S, Chechik R, Breskin A et al. New prospective for non-invasive detection, grading, size evaluation, and tumor location of prostate cancer. Prostate 2010; 70: 1701 - 1708.
21. Zaichick V, Sviridova TV, Zaichick SV. Zinc in the human prostate gland: Normal, hyperplastic and cancerous. Int Urol Nephrol 1997; 29: 565 - 574.
22. Costello LC, Franklin RB. Prostatic fluid electrolyte composition for the screening of prostate cancer: A potential solution to a major problem. Prostate Cancer Prostatic Dis 2009; 12: 17-24.
23. Costello LC, Liu Y, Franklin RB, Kennedy MC. Zinc inhibition of mitochondrial aconitase and its importance in citrate metabolism of prostate epithelial cells. J Biol Chem 1997; 272: 28875 - 28881.
24. Cheng LL, Burns MA, Taylor JL, He W, Halpern EF, McDougal WS et al. Metabolic characterization of human prostate cancer with tissue magnetic resonance spectroscopy. Cancer Res 2005; 65: 3030 - 3034.
25. Serkova NJ, Gamito EJ, Jones RH, O'Donnell C, Brown JL, Green S et al. The metabolites citrate, myo-inositol, and spermine are potential age-independent markers of prostate cancer in human expressed prostatic secretions. Prostate 2008; 68: 620 - 628.
26. Mueller-Lisse UG, Scherr MK. Proton MR spectroscopy of the prostate. Eur J Radiol 2007; 63: 351 - 360.
27. Cheng LL, Ma MJ, Becerra L, Ptak T, Tracey I, Lackner A et al. Quantitative neuropathology by high resolution magic angle spinning proton magnetic resonance spectroscopy. Proc Natl Acad Sci USA 1997; 94: 6408 - 6413.
28. Burns MA, Taylor JL, Wu CL, Zepeda AG, Bielecki A, Cory D et al. Reduction of spinning sidebands in proton NMR of human prostate tissue with slow highresolution magic angle spinning. Magn Reson Med 2005; 54: 34-42.
29. Cheng LL, Wu C, Smith MR, Gonzalez RG. Non-destructive quantitation of spermine in human prostate tissue samples using HRMAS 1H NMR spectroscopy at 9.4T. FEBS Lett 2001; 494: 112 - 116.
30. Rhodes DR, Sanda MG, Otte AP, Chinnaiyan AM, Rubin MA. Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. J Natl Cancer Inst 2003; 95: 661 - 668.
31. Ross AE, Loeb S, Landis P, Partin AW, Epstein JI, Kettermann A et al. Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol 2010; 28: 2810 - 2816.
32. Coen JJ, Feldman AS, Smith MR, Zietman AL. Watchful waiting for localized prostate cancer in the PSA era: What have been the triggers for intervention? BJU Int 2011; 107: 1582 - 1586.
33. Smith AD, Phillips JL. Limitations and use of PSA velocity in the diagnosis and characterization of prostate cancer. Nat Clin Pract Urol 2007; 4: 576 - 577.
34. Yu X, Loeb S, Roehl KA, Han M, Catalona WJ. The association between total prostate specific antigen concentration and prostate specific antigen velocity. J Urol 2007; 177: 1298 - 1302; discussion 1298-1302.
35. Berger AP, Deibl M, Steiner H, Bektic J, Pelzer A, Spranger R et al. Longitudinal PSA changes in men with and without prostate cancer: Assessment of prostate cancer risk. Prostate 2005; 64: 240 - 245.
36. Qian F, Zhang C, Zhang Y, He W, Gao X, Hu P et al. Visible light excitable Zn2+ fluorescent sensor derived from an intramolecular charge transfer fluorophore and its in vitro and in vivo application. J Am Chem Soc 2009; 131: 1460 - 1468.